艾媒报告 | 2017-2018中国移动电商行业研究报告

iiMedia Research(艾媒咨询)数据显示，2017年移动电商用户规模达4.73亿人，增长13.2%，2018年预计能增长至5.12亿人。艾媒咨询分析师认为，随着电商逐步成熟，新零售、拼购电商概念的提出，农村网民规模的增大，移动电商市场仍存在较大的发展的空间。

艾媒咨询|2021年夜间用药行业研究报告

本报告研究涉及企业/品牌/案例：美团，京东到家，饿了么

国内人口基数增长以及人们对于健康管理意识的增强，使得夜间用药市场的需求度也保持在较高的水平。iiMedia Research(艾媒咨询)数据显示，约89.9%受访者表示近一年有过夜间生病或者家人朋友需要用药的经历，并且，群众对夜间用药种类的需求丰富，并且在夜间各个时段的急性疾病需求都普遍较高。为此，04年起政府已经倡导24小时药店以满足用户需求。但是研究发现，“晚上买药难”是夜间生病人士普遍提及的关键词，即时配送平台兴起或成解决夜间用药新机遇。
The growth of the domestic population base and the increase of people's awareness of health management have kept the demand for night medication in the market at a relatively high level. According to data from iiMedia Research, about 89.9% of the interviewees said that they have had the experience of getting sick at night or needing medication at night in the past year. Moreover, the masses have a rich demand for medication at night, and acute illnesses at various times during the night. Disease needs are generally high. For this reason, since 2004, the government has advocated 24-hour pharmacies to meet user needs. However, the study found that "difficult to buy medicine at night" is a key word commonly mentioned by people who are sick at night. The rise of instant delivery platforms may be a new opportunity to solve night medicine.

艾媒咨询｜2024年中国专升本学历培训市场趋势分析报告

近年来，国家出台了一系列政策以引导和规范学历培训行业，为其发展奠定良好的环境基础。与此同时，就业形势的严峻性以及个人学历受重视程度的日益提高，也为学历培训行业带来了前所未有的发展机遇。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年中国专升本学历培训市场趋势分析报告》数据显示，超九成的专升本人群在备考期间更倾向于报班学习，专升本一类的培训机构将迎来利好。为更好地满足学员的学习需求和市场需求，培训机构需不断创新教育模式、提升教育质量和服务水平、拓展海外市场以及实现数字化和智能化转型。
In recent years, the state has introduced a series of policies to guide and regulate the academic training industry, laying a good environmental foundation for its development. At the same time, the severity of the employment situation and the increasing importance of personal qualifications has also brought unprecedented opportunities for the development of the academic training industry. According to the latest Research Report 2024 China Postsecondary Degree Training Market Trend Analysis Report released by iiMedia Research, a third-party data mining and analysis institution of the global new economy industry, more than 90% of the college-educated people are more inclined to enroll in classes during the preparation for the examination, and training institutions for college-educated people will usher in a favourable situation, and in order to satisfy more consumer demand, training institutions need to continuously innovate education models, improve education quality and service, and expand overseas markets as well as digital intelligent transformation. In order to better meet the learning needs of students and market demand, training institutions need to constantly innovate education models, improve education quality and service level, expand overseas markets, and realize digital and intelligent transformation.

德勤-E级精算师的兴起（英文版）

人工智能、自动化、机器学习。科技发展日新月异，正迅速为工作模式创造一个全新的未来。这个改革正在以加速的步伐重新定义工作，而人和机器能够协力工作的可能将改变整个行业。随着这个令人兴奋的未来逐步展开，精算专业也将经历剧烈的变化，并为精算师开启全新的工作机会，造就他们担起更具活力的商业角色。

艾媒报告|2020-2021年中国医疗电商行业发展趋势及标杆企业分析报告

本报告研究涉及企业/品牌/案例：平安好医生,康爱多,阿里健康,健客,鱼跃医疗；其他提及企业/品牌：益药购,1药网,九州通网,心诺,我的医药网,好药师,美之氧,药京采,七乐康,欧姆龙,普天药城网,氧生活,未名企鹅,爱康多,巨人,药药好,京东大药房,康祝,药品终端网,360好药,可孚,药师帮,药房网,艾润科技,药便宜,八百方

2020年3月9日，全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020-2021年中国医疗电商行业发展趋势及标杆企业分析报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据，对2020年中国医疗电商产业发展进行分析。本报告主要通过医药电商和家用医疗器械两方面，对医疗电商产业上下游深入探究运行模式，并对鱼跃集团、平安好医生、爱康多等典型企业进行案例分析，以此对中国医疗电商行业发展进行趋势预判。2019年中国医药电商行业发展规模继续增大，涌现出许多新型零售方式。越来越多医药企业涌入B2B主流市场，B2C市场规模也随着消费者健康意识的提升以及网购消费习惯的固定而得到较大发展；越来越多药企也开始开展O2O业务。以药到医、“医+药”发展的模式也受到普遍认可。特别在新型冠状病毒肺炎疫情影响下，医疗电商以其独特的互联网优势在抗击疫情中发挥了重要作用。在此契机下，医疗电商行业将在2020年迎来重大普及发展的历史机遇期。

In 2019, the scale of China's pharmaceutical e-commerce industry continues to increase, and many new retail methods have emerged. More and more pharmaceutical companies have entered the mainstream B2B market, and the scale of the B2C market has also grown significantly with the improvement of consumers' health awareness and the fixation of online shopping consumption habits; more and more pharmaceutical companies have begun to develop O2O business. The development model from medicine to medicine and "medicine + medicine" has also been widely recognized. Especially under the influence of the new coronavirus pneumonia epidemic, medical e-commerce has played an important role in fighting the epidemic with its unique Internet advantage. With this opportunity, the medical e-commerce industry will usher in a period of historical opportunities for significant popularization in 2020.

艾媒咨询 | 2023-2024年全球与中国医药电商市场与发展趋势研究报告

近年来医药分离新政和试点工作不断，药方外流是一大趋势。在新技术、新动能的驱动下，“互联网+药品流通”的趋势将重塑药品流通行业生态布局，医药电商行业逐步进入转型升级创新发展阶段。 全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2023-2024年全球与中国医药电商市场与发展趋势研究报告》数据显示，2016-2022年中国医药电商市场规模逐年增长，增速总体呈下降趋势，2022年医药电商市场规模为2486.0亿元，同比增长10.0%。

艾媒报告 |2019全球与中国医药电商市场与发展趋势研究报告

本报告研究涉及企业/品牌/案例：天猫医馆，七乐康，京卫大药房，阿里健康大药房,京东大药房,健客, 1药网,360好药,八百方,818医药网,CVS,Walgreens ,RiteAid ,开心人网上药店，药房网，药材买卖网，珍材网，中药材天地网，商康网，科欣医药，医药在线，我的医药网，药品交易网，药品终端网，药师帮，海王晨星，快方送药，药给力，搜药送，药急送，U医U药，叮当送药，健客网上药店，康爱多掌上药店，问药，好药师，111集团，中宏保险，医联，腾讯，仁和药业，浙江扁鹊，漱玉平民，华人健康，一树药业，德生堂

2019中国医药电商主要形成了B2C、B2B、O2O三种模式，B2C模式体量稳定在6%左右，规模呈增长趋势，预计2019年的市场交易额将达到554.6亿元;B2B模式下，西药类产品的需求比例较高，达87.1%，中药材、传统药品和第三方交易等都形成了专属B2B平台;而近几年兴起的O2O模式，主要通过“引流-转化-消费-反馈”等实现盈利，但区域覆盖度和消费者的信任度需要提高。iiMedia Research(艾媒咨询)大数据监测显示，目前1药网、健客网上药店、康爱多掌上药店的的综合实力排行较强。

2019 China's pharmaceutical e-commerce mainly formed three modes of B2C, B2B and O2O. The volume of B2C model is stable at around 6%, and the scale is increasing. It is expected that the market transaction volume in 2019 will reach 55.46 billion yuan; in B2B mode, western medicine The demand ratio of products is relatively high, reaching 87.1%. Chinese herbal medicines, traditional medicines and third-party transactions have formed a proprietary B2B platform. In recent years, the O2O model has emerged mainly through “drainage-conversion-consumption-feedback”. Achieve profitability, but regional coverage and consumer trust need to be improved. iiMedia Research (Ai Media Consulting) big data monitoring shows that the current comprehensive strength of 1 drug network, Jianke online pharmacy, Kang Aiduo pharmacy is strong.

艾媒咨询|2021年中国夜间用药年度观察报告

本报告涉及的案例/品牌/企业：美团买药，叮当快药

在众多社会服务中，夜间用药成为人们最关注的夜间社会服务之一，近年来，各地相关行政管理机构也陆续出台相关扶持政策，鼓励商家上线夜间送药平台、发展24小时药店，提供夜间送药服务，推动解决“夜间买药难”问题。近日，iiMedia Research(艾媒咨询)最新发布《2021年中国夜间用药年度观察报告》，基于2021年初至2021年末的监测数据，对中国夜间用药市场持续追踪。报告显示，年初有61.2%的用户夜间生病选择忍，而年底这一数字降至52.1%，据推算年末夜间用药受益群体新增约4000万人。报告指出，日渐成熟的中国外卖送药平台，成为解决夜间用药的重要参与者。通过一年的发展，在美团买药“小黄灯”计划等24小时药店惠民工程的推动下，线上24小时药店数量增加、夜间买药配送速度更快、服务保障更加成熟，用户知晓度有了较大提升，夜间买药难的问题得到有效缓解。
Among many social services，night medication has become one of the night social services that people pay most attention to. In recent years，relevant administrative agencies around the country have also successively issued relevant support policies to encourage businesses to launch night medication delivery platforms，develop 24-hour pharmacies，provide night medication delivery services， and promote the solution of the problem of "difficulty in buying drugs at night". Recently， iiMedia Research released the annual observation report on nighttime medication in China in 2021，which continuously tracks China's nighttime medication market based on the monitoring data from the beginning of 2021 to the end of 2021. The report shows that at the beginning of the year， 61.2% of users chose to tolerate illness at night，while at the end of the year，the figure fell to 52.1%. It is estimated that about 40 million people will benefit from night medication at the end of the year.The report points out that the increasingly mature Chinese takeout delivery platform has become an important participant in solving the problem of night medication. Through one year's development，driven by the 24-hour pharmacy benefit project such as the "small yellow light" plan of meituan drug purchase， the number of online 24-hour pharmacies has increased，the speed of drug purchase and distribution at night is faster，the service guarantee is more mature，the user awareness has been greatly improved，and the problem of difficult drug purchase at night has been effectively alleviated.

艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告

本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药

国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。

中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。

Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well.

艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告

本报告研究涉及企业/品牌/案例：同仁堂、香雪制药、白云山。

数据显示，2020年第三季度，中药材价格指数迎来上涨周期。艾媒咨询分析师认为，受动物类等少数品种拉动影响，预计2020年10-11月中药材指数会持续走高，但是在12月维稳。据调查，绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营，采取减少压货炒作等经营方式。因而，预计中药材市场在2020年末旺季会有一波行情的走高，但随着旺季结束，明年年初的价格会重新回落，随着疫情的常态化，中药材市场行情预期会呈周期性波动的态势。

Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation.